NO893373L - Et humant rhino-virus-reseptor-protein som hemmer virusinfeksjon. - Google Patents

Et humant rhino-virus-reseptor-protein som hemmer virusinfeksjon.

Info

Publication number
NO893373L
NO893373L NO89893373A NO893373A NO893373L NO 893373 L NO893373 L NO 893373L NO 89893373 A NO89893373 A NO 89893373A NO 893373 A NO893373 A NO 893373A NO 893373 L NO893373 L NO 893373L
Authority
NO
Norway
Prior art keywords
receptor
hrv
virus
detergent
receptor protein
Prior art date
Application number
NO89893373A
Other languages
English (en)
Norwegian (no)
Other versions
NO893373D0 (no
Inventor
Jeffrey Greve
Alan Mcclelland
Gary Davis
Original Assignee
Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Therapeutics Inc filed Critical Molecular Therapeutics Inc
Publication of NO893373D0 publication Critical patent/NO893373D0/no
Publication of NO893373L publication Critical patent/NO893373L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO89893373A 1988-09-01 1989-08-22 Et humant rhino-virus-reseptor-protein som hemmer virusinfeksjon. NO893373L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23957188A 1988-09-01 1988-09-01
US26242888A 1988-10-25 1988-10-25
US39066289A 1989-08-10 1989-08-10

Publications (2)

Publication Number Publication Date
NO893373D0 NO893373D0 (no) 1989-08-22
NO893373L true NO893373L (no) 1990-03-02

Family

ID=27399251

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89893373A NO893373L (no) 1988-09-01 1989-08-22 Et humant rhino-virus-reseptor-protein som hemmer virusinfeksjon.

Country Status (15)

Country Link
US (1) US7132395B1 (fr)
EP (1) EP0362531B1 (fr)
JP (1) JP3253064B2 (fr)
AT (1) ATE186552T1 (fr)
AU (1) AU637324B2 (fr)
CA (1) CA1339193C (fr)
DE (1) DE68929096T2 (fr)
DK (1) DK174095B1 (fr)
ES (1) ES2141076T3 (fr)
FI (1) FI894065L (fr)
GR (1) GR3032456T3 (fr)
IL (1) IL91454A (fr)
NO (1) NO893373L (fr)
NZ (1) NZ230474A (fr)
PT (1) PT91570B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01502879A (ja) * 1987-02-26 1989-10-05 ダナ　ファーバー　キャンサー　インスティテュート Ｌｆａ―１のクローニング
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
EP0362531B1 (fr) 1988-09-01 1999-11-10 Bayer Corporation Protéine du récepteur du rhinovirus humain, qui inhibe le caractère infectieux du virus
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
NO900155L (no) * 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
JPH04505009A (ja) * 1989-03-09 1992-09-03 ダナ・ファーバー・キャンサー・インスティチュート クローニングｌｆａ―１
ES2177695T3 (es) * 1989-03-16 2002-12-16 Blood Res Center Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
WO1991018010A1 (fr) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition d'infection virale a l'aide de peptides analogues a la molecule-1 d'adhesion intercellulaire et/ou d'analogues de ces peptides
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US5288854A (en) * 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
US5891841A (en) * 1991-06-11 1999-04-06 The Center For Blood Research, Inc. Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
EP0578819A4 (fr) * 1992-01-27 1994-10-12 Icos Corp Proteine apparentee a icam.
US6153395A (en) * 1992-01-27 2000-11-28 Icos Corporation ICAM-related protein
US6100383A (en) * 1992-01-27 2000-08-08 Icos Corporation Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
US5525487A (en) * 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US6818743B1 (en) 1992-01-27 2004-11-16 Icos Corporation I-CAM related protein
US5989843A (en) * 1992-01-27 1999-11-23 Icos Corporation Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
US5532127A (en) * 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
AU710965B2 (en) * 1992-06-22 1999-09-30 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
AU5466794A (en) * 1992-11-18 1994-06-08 Helsinki University Licensing Ltd Oy Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
DK0885010T3 (da) * 1996-03-06 2003-09-15 Boehringer Ingelheim Pharma Pulverformigt lægemiddel indeholdende intercellulært adhæsionsmolekyle
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
EP1682537B1 (fr) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulateurs de l'adhesion cellulaire
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
WO2009139817A2 (fr) 2008-04-15 2009-11-19 Sarcode Corporation Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
WO2011050175A1 (fr) 2009-10-21 2011-04-28 Sarcode Corporation Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
WO2014018748A1 (fr) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Inhibiteur de lfa-1 et polymorphe de celui-ci
CA3014764A1 (fr) 2016-02-25 2017-08-31 Applied Biological Laboratories, Inc. Compositions et procedes de protection contre des agents pathogenes et des substances irritantes aeriens
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4209526A (en) 1977-08-05 1980-06-24 Sterling Drug Inc. Antiviral arylenedioxyalkyl substituted pyrazoles
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
JPS551594A (en) 1978-06-12 1980-01-08 Corning Glass Works Measuring antigen receptor on cell membrane
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4427653A (en) 1981-01-26 1984-01-24 President And Fellows Of Harvard College Method of making monoclonal antibodies
US4372976A (en) 1981-08-07 1983-02-08 Sterling Drug Inc. Novel aryl-aliphatic ketone and its use as an antiviral agent
US4451476A (en) 1982-12-13 1984-05-29 Sterling Drug Inc. Isoxazoles as antiviral agents
US4843087A (en) 1983-08-29 1989-06-27 Sterling Drug Inc. Di-heterocyclic compounds and their use as antiviral agents
EP0169146A3 (fr) * 1984-07-20 1988-07-20 Merck & Co. Inc. Anticoprs monoclonaux dirigés contre le récepteur cellulaire du rhinovirus humain
JPS6181798A (ja) 1984-07-23 1986-04-25 ベクトン・デイツキンソン・アンド・カンパニ− 細胞リセプタ−の回収
DE3505148A1 (de) 1985-02-15 1986-10-30 Boehringer Ingelheim International GmbH, 6507 Ingelheim Polypeptide des rhinovirusstammes hrv2 sowie die hierfuer codierenden dna-molekuele
CA1280753C (fr) 1985-07-02 1991-02-26 Philip Michael Carabateas Methode de preparation de derives de substitution heterocycliques de phenoxyalkylisoxasoles et de phenoxyalkylfuranes
EP0227604A3 (fr) 1985-12-23 1989-01-18 Sandoz Ag Emploi d'oligopeptides dans le traitement d'infections virales
EP0261403A3 (fr) 1986-08-23 1988-04-13 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Polypeptide de rhinovirus souche HRV89, et molécule d'ADN qui l'encode
EP0280578B1 (fr) 1987-02-26 1993-12-15 Dana-Farber Cancer Institute, Inc. Purification de LFA-3
JPH01502879A (ja) 1987-02-26 1989-10-05 ダナ　ファーバー　キャンサー　インスティテュート Ｌｆａ―１のクローニング
US5603932A (en) 1987-04-14 1997-02-18 Boehringer Ingelheim International Gmbh Receptor of the minor human rhinovirus receptor group
US5304636A (en) 1987-04-14 1994-04-19 Boehringer Ingelheim International Gmbh Receptor for the human rhinovirus minor group
DE3712678A1 (de) 1987-04-14 1988-10-27 Boehringer Ingelheim Int Rezeptor der kleinen rhinovirus rezeptor gruppe
US5831036A (en) 1987-05-04 1998-11-03 Dana Farber Cancer Institute Soluble fragments of human intercellular adhesion molecule-1
AU629189B2 (en) 1987-05-04 1992-10-01 Dana-Farber Cancer Institute Intercellular adhesion molecules and their binding ligands
DE3854536T2 (de) 1987-05-04 1996-03-07 Dana Farber Cancer Inst Inc Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US4956281A (en) 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5109123A (en) 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
ES2064327T3 (es) 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.
US5081228A (en) 1988-02-25 1992-01-14 Immunex Corporation Interleukin-1 receptors
CA1341055C (fr) * 1987-12-08 2000-07-18 Alan Mcclelland Lignees cellulaires transfectantes exprimant le recepteur majeur du rhinovirus chez l'homme
US5395929A (en) 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
EP0372056A4 (en) 1988-05-04 1991-05-15 Dana Farber Cancer Institute Protein micelles
DE68923048T2 (de) 1988-08-23 1995-11-16 Dana Farber Cancer Inst Inc Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
EP0362531B1 (fr) 1988-09-01 1999-11-10 Bayer Corporation Protéine du récepteur du rhinovirus humain, qui inhibe le caractère infectieux du virus
US6514936B1 (en) * 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6143298A (en) 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6051231A (en) 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ES2077572T3 (es) 1988-09-28 1995-12-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular, y sus ligandos de fijacion.
AU4412889A (en) 1988-09-28 1990-04-18 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5372933A (en) 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5235049A (en) 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
PT92900A (pt) 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
CA2008368C (fr) 1989-01-24 2003-04-08 Jeffrey Greve Molecule soluble apparentee a l'icam-i mais distincte
NO900155L (no) 1989-01-24 1990-07-25 Molecular Therapeutics Inc Et opploeselig molekyl som er relatert til, men forskjellig fra icam-1.
WO1990010646A1 (fr) 1989-03-09 1990-09-20 Dana Farber Cancer Institute Recepteurs d'adherence de leucocyte
JPH04505009A (ja) 1989-03-09 1992-09-03 ダナ・ファーバー・キャンサー・インスティチュート クローニングｌｆａ―１
DE69000248T2 (de) 1989-03-09 1993-01-07 Boehringer Ingelheim Pharma Verwendung von interzellularen adhaesions-molekuelen und deren bindungsliganden bei der behandlung von asthma.
HU217792B (hu) 1989-03-16 2000-04-28 Dana Farber Cancer Institute Eljárás intercelluláris adhéziós molekula (ICAM-1) oldható származékai és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2177695T3 (es) 1989-03-16 2002-12-16 Blood Res Center Uso de derivados funcionales de la molecual de adhesion intercelular icam-1 en terapia antiviral.
WO1990013316A1 (fr) 1989-04-28 1990-11-15 Baylor College Of Medicine Dissemination de cellules infectees par l'hiv-1
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
WO1991018011A1 (fr) 1990-05-15 1991-11-28 Swinburne Limited Inhibition d'adhesion cellulaire a l'aide de peptides analogues a la molecule-1-d'adhesion intercellulaire et/ou d'analogues de ces peptides
WO1991018010A1 (fr) 1990-05-15 1991-11-28 Swinburne Limited Inhibition d'infection virale a l'aide de peptides analogues a la molecule-1 d'adhesion intercellulaire et/ou d'analogues de ces peptides
EP0459577A3 (en) 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
KR100206524B1 (ko) 1990-07-13 1999-07-01 어니스트 엠. 해데드 씨디 53 세포 표면 항원 및 그를 암호화하는 재조합 디엔에이
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US5686581A (en) 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US6107461A (en) 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
DK0468257T3 (da) 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
US5871733A (en) 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
JPH06500555A (ja) 1990-08-27 1994-01-20 カイロン　コーポレイション 病気の処置のためのペプチドの薬物
CA2092801A1 (fr) 1990-10-03 1992-04-04 Randall Barton Methode de traitement de l'inflammation a l'aide d'anticorps anti-idiotypiques
US5288854A (en) 1990-11-28 1994-02-22 Center For Blood Research, Inc. Functional derivatives of ICAM-1 which are substantially capable of binding to LFA-1 but are substantially incapable of binding to MAC-1
EP0517895B1 (fr) 1990-12-14 1996-11-20 Cell Genesys, Inc. Chaines chimeriques utilisees comme voies de transduction de signal associe a un recepteur
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
EP0510483A1 (fr) 1991-04-22 1992-10-28 Boehringer Ingelheim Pharmaceuticals Inc. Procédé pour la détection des virus
US5223396A (en) 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
US5240694A (en) 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
AU2763692A (en) 1991-10-02 1993-05-03 Boehringer Ingelheim Pharmaceuticals, Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
WO1993006850A1 (fr) 1991-10-03 1993-04-15 The Center For Blood Research Erythrocytes infectes par plasmodium falciparum et lies a l'icam-1 et au cd36
DE69229275T2 (de) 1991-10-04 1999-12-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
US5861151A (en) 1991-12-20 1999-01-19 Bristol-Myers Squibb Co Soluble fusion molecules with binding specificity for cell adhesion molecules
US5525487A (en) 1992-01-27 1996-06-11 Icos Corporation DNA encoding I-CAM related protein
US5532127A (en) 1992-01-27 1996-07-02 Icos Corporation Assay for 1-CAM related protein expression
EP0578819A4 (fr) 1992-01-27 1994-10-12 Icos Corp Proteine apparentee a icam.
PT566554E (pt) 1992-03-13 2000-09-29 Monsanto Co Producao de proteinas recombinantes usando promotores do virus de herpes e transactivadores vp16
EP0604624A4 (fr) 1992-06-22 1997-03-12 Miles Inc Formes multimeres de la proteine propre au recepteur du rhinovirus humain.
HUT68246A (en) 1992-07-08 1995-06-28 Boehringer Ingelheim Int Receptor derivatives with binding sites for human rhinoviruses
US5580969A (en) 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA
AU5466794A (en) 1992-11-18 1994-06-08 Helsinki University Licensing Ltd Oy Peptides from human icam-2 and from human icam-1 and their analogs for use in therapy and diagnosis
EP0757697A4 (fr) 1994-04-12 2000-05-17 Boehringer Ingelheim Pharma Utilisation d'agents bloquant l'interaction molecule d'adhesion intercellulaire/recepteur dans le traitement d'une infection respiratoire virale
CA2188287A1 (fr) 1994-04-19 1995-10-26 Stephen Benedict Peptides a chaine courte a base d'icam-1/lfa-1 et leur methode d'utilisation
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
AU3159595A (en) 1994-08-30 1996-03-22 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity
US5733540A (en) 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
ES2222775B1 (es) 2002-01-31 2006-12-16 Laboratorios Indas, S.A. Procedimiento para la deteccion de una predisposicion a una enfermedad cardiovascular.
AUPS161102A0 (en) 2002-04-08 2002-05-16 Industrial Engineering Technology Pty Ltd Improved gas burner

Also Published As

Publication number Publication date
FI894065A0 (fi) 1989-08-30
JPH02238892A (ja) 1990-09-21
EP0362531B1 (fr) 1999-11-10
CA1339193C (fr) 1997-08-05
DK174095B1 (da) 2002-06-10
IL91454A0 (en) 1990-04-29
GR3032456T3 (en) 2000-05-31
DK431289D0 (da) 1989-08-31
AU637324B2 (en) 1993-05-27
NO893373D0 (no) 1989-08-22
DK431289A (da) 1990-03-02
IL91454A (en) 1995-08-31
JP3253064B2 (ja) 2002-02-04
AU4027189A (en) 1990-03-08
ATE186552T1 (de) 1999-11-15
EP0362531A1 (fr) 1990-04-11
FI894065A7 (fi) 1990-03-02
PT91570A (pt) 1990-03-30
NZ230474A (en) 1993-03-26
DE68929096D1 (de) 1999-12-16
DE68929096T2 (de) 2000-05-11
ES2141076T3 (es) 2000-03-16
FI894065L (fi) 1990-03-02
US7132395B1 (en) 2006-11-07
PT91570B (pt) 1995-05-31

Similar Documents

Publication Publication Date Title
NO893373L (no) Et humant rhino-virus-reseptor-protein som hemmer virusinfeksjon.
ATE98376T1 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
UA41870C2 (uk) Спосіб направлення клітинної відповіді на інфекційний агент, клітину, інфіковану вказаним агентом, пухлинну, злоякісну клітину або аутоімунну клітину (варіанти), клітина, яка експресує мембранозв'язаний білковий химерний рецептор (варіанти), днк,що кодує химерний рецептор, вектор, спосіб лікування інфекції вірусу імунодефіциту(варіанти)
RU97115895A (ru) Переключение клеточного иммунитета, осуществляемое с помощью тирозин-специфических протеинкиназных химер
DE69232906T2 (de) Detektion des Hepatis-C Virus.
KR890002547A (ko) Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
ES2050114T3 (es) Anticuerpos monoclonales humanos para el virus asociado a la linfoadenopatia.
FI885868A7 (fi) Menetelmä immuunikatoviruksen vasta-aineiden havaitsemiseksi
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
BE888855A (fr) Procede d'obtention de preparations de toxoplasmes pour le diagnostic de la toxoplasmose, et preparations ainsi obtenues
Iversen et al. The major internal protein, p27, of a retrovirus-like particle is expressed in blood lymphocytes from psoriatic patients
TR27329A (tr) Yeni metazoan parazit antigenler, bunlari kodlayan nükleik asidler.
DK100888A (da) Fremgangsmaade til at rense rekombinant pres-1/s-2/s hepatitis b antigen fra gaer
Rødahl et al. Analysis of circulating immune complexes from patients with ankylosing spondylitis by gel electrophoresis and immunoblotting using antiserum against a psoriasis associated retrovirus-like particle.
DK173905B1 (da) HIV-beslægtede polypeptider, diagnostiske systemer og analysemetoder
FI915333A7 (fi) T-lymfotrooppisten retrovirusten monoklonaalisia vasta-aineita
Aronstein et al. Lung-stage expression of a major schistosome surface antigen
Papamichail et al. Binding of native and aggregated human γ-globulin by mouse lymphoid cells and fibroblasts
FI870500A7 (fi) Reagenssi virus-antigeenin vasta-aineen määrittämiseksi.
MD950343A (ro) Metodă de diagnosticare a leucozei
Zhang et al. AChR specific T lymphocytes in Myasthenia Gravis
Matsiota-Bernard et al. Inhibition of in vitro HIV infection by trinitrophenyl-protein conjugates
Koethe et al. Lysis of Neuraminidase-Treated Paroxysmal Nocturnal Hemoglobinuria (PNH) Erythrocytes in Normal Human Serum
DE4112743A1 (de) Synthetische core-peptide zur bestimmung von hcv-antikoerpern und hcv-antigenen, mittel dazu und ihre verwendung in diesen nachweis-verfahren
RU95122100A (ru) Способ иммунокоррекции носителя патогена